More actions
The edit can be undone. Please check the comparison below to verify that this is what you want to do, and then publish the changes below to finish undoing the edit.
| Latest revision | Your text | ||
| Line 29: | Line 29: | ||
Between 1999 and 2005, Eli Lilly promoted Zyprexa in primary-care for treatment of Dementia and Alzheimer's Dementia, without the approval of the [[Food and Drug Administration]].<ref name=:0>{{News citation|title=Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations <nowiki>[of]</nowiki> Off-label Promotion of Zyprexa|url=https://www.justice.gov/opa/pr/eli-lilly-and-company-agrees-pay-1415-billion-resolve-allegations-label-promotion-zyprexa|date=2009-01-15|newspaper=Office of Public Affairs}}</ref> | Between 1999 and 2005, Eli Lilly promoted Zyprexa in primary-care for treatment of Dementia and Alzheimer's Dementia, without the approval of the [[Food and Drug Administration]].<ref name=:0>{{News citation|title=Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations <nowiki>[of]</nowiki> Off-label Promotion of Zyprexa|url=https://www.justice.gov/opa/pr/eli-lilly-and-company-agrees-pay-1415-billion-resolve-allegations-label-promotion-zyprexa|date=2009-01-15|newspaper=Office of Public Affairs}}</ref> | ||
In 2007, Eli Lilly had been sued by the U.S government, for $1.415 billion, due to the unapproved promotion of Zyprexa in primary-care.<ref name=:0 /> | In 2007, Eli Lilly had been sued by the [[United States of America|U.S government]], for $1.415 billion, due to the unapproved promotion of Zyprexa in primary-care.<ref name=:0 /> | ||
==References== | ==References== | ||